Recombinant Cynomolgus/Rhesus Macaque Nectin-4 Protein, CF

Immobilized Recombinant Cynomolgus Monkey Nectin‑4(Catalog # 9996-N4) supports the adhesion of NIH‑3T3 mouse embryonic fibroblastcells. The ED50 for this effect is 0.1-1 μg/mL.

2 μg/lane of Recombinant Cynomolgus Monkey Nectin‑4 was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 38-45 kDa.

• Reactivity: Pm-Cm, RM
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus/Rhesus Macaque Nectin-4 Protein, CF Summary

• Additional Information: His-tag
• Details of Functionality: Measured by the ability of the immobilized protein to support the adhesion of NIH‑3T3 mouse embryonic fibroblast cells. The ED₅₀ for this effect is 0.1-1 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived Nectin-4 protein
  Gly32-Ser349, with a C-terminal 6-His tag
• Accession #: XP_005541277.1
• N-terminal Sequence: Gly32
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 35 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 38-45 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage:
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus/Rhesus Macaque Nectin-4 Protein, CF

• EDSS1
• Ig superfamily receptor LNIR
• LNIR
• LNIRnectin 4
• Nectin4
• Nectin-4
• poliovirus receptor-related 4
• poliovirus receptor-related protein 4
• PRR4
• PRR4DKFZp686K05193
• PVRL4

Background

Nectin-4, also known as Poliovirus receptor-related protein 4 (Gene name: PVRL4), is a 66-kDa type I transmembrane glycoprotein belonging to the Nectin immunoglobulin superfamily (1). The Latin word necto means "to connect", indicating the role of nectins in Ca²⁺‑independent cell-cell adhesion (2). Nectin-4 forms homodimers in cis, followed by interactions in trans with Nectin-1 or -4 (1‑3). Human Nectin-4 is normally expressed in the placenta, especially in endothelial cells, while in the mouse it is found in the embryo, lung, testis and brain (1, 4, 5). In many human ductal breast or non-small cell lung carcinomas, Nectin‑4 is up-regulated and a soluble 43-kDa form is found in the plasma (4-6). This form is generated from the membrane protein via the action of TACE/ADAM-17 (6). Nectin extracellular domains (ECDs) contain three Ig-like domains: an N‑terminal V-type that mediates ligand binding, and two C2-type (1, 3). Within the ECD, cynomolgus Nectin-4 shares 99%, and 91% amino acid sequence identity with human and mouse Nectin-4, respectively. In forming adherens junctions, trans interactions of Nectin-4 initiate cell-cell interactions and recruit intracellular cadherins through afadin and other junctional proteins (1, 2). These interactions organize the actin cytoskeleton, strengthen attachment to basement membrane and promote further cell-cell connections (2, 7). In humans, mutation of Nectin-4 has been correlated with ectodermal dysplasia-syndactyly syndrome, indicating a role for Nectin-4 in human development (7). High Nectin-4/PVRL4 expression was associated with poor-prognosis in some invasive breast cancers and may be a new promising prognostic biomarker and specific therapeutic target (8).

1. Reymond, N. et al. (2001) J. Biol. Chem. 276:43205.
2. Takai, Y. et al. (2008) Nat. Rev. Mol. Cell Biol. 9:603.
3. Fabre, S. et al. (2002) J. Biol. Chem. 277:27006.
4. Fabre-Lafay, S. et al. (2007) BMC Cancer 7:73.
5. Takano, A. et al. (2009) Cancer Res. 69:6694.
6. Fabre-Lafay, S. et al. (2005) J. Biol. Chem. 280:19543.
7. Brancati, F. et al. (2010) Am. J. Hum. Genet. 87:265.
8. M-Rabet, M. et al. (2017) Ann. Oncol. 28:769.

Bioinformatics

• Uniprot:
  • XP_005541277.1()